4-[3-Methoxy-4-[[5-methyl-7-oxo-8-[3-(prop-2-enoylamino)phenyl]pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-[3-Methoxy-4-[[5-methyl-7-oxo-8-[3-(prop-2-enoylamino)phenyl]pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylic acid
• 英文别名: 4-[3-methoxy-4-[[5-methyl-7-oxo-8-[3-(prop-2-enoylamino)phenyl]pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylic acid
• 化学式: C₂₉H₂₉N₇O₅
• 分子量: 555.6
• InChiKey: XFSHSXYFBOIRJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  41
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  140
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• SUBSTITUTED 7-OXO-PYRIDO [2, 3-D]PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS
  申请人：Amgen Inc.

  公开号：EP2961750A1

  公开（公告）日：2016-01-06
• [EN] SUBSTITUTED 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS<br/>[FR] 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS À EGFR/ERBB2
  申请人：AMGEN INC

  公开号：WO2014134308A1

  公开（公告）日：2014-09-04

  The invention encompasses compounds represented by the following general structures: formula (I) and formula (II), wherein X; R1-R3; R11; R12; and R14 are as defined in the claims and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.